MAP4K Inhibitor

GNE-495 (Standard) is the analytical standard of GNE-495 (HY-100343). This product is intended for research and analytical applications. GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.

HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC₅₀ value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy.

HPK1-IN-48 (compound 14g) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a IC₅₀ of 0.15 nM. HPK1-IN-48 significantly suppresses the phosphorylation of SLP76 with a IC₅₀ of 27.92 nM.

HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research.

HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a K_i of 100 nM. HPK1-IN-24 has the potential for cancer research.

HPK1-IN-18 is an HPK1 kinase inhibitor with anticancer cell activity. HPK1-IN-18 inhibits HPK1 kinase activity. HPK1-IN-18 can be used for cancer research.

HPK1-IN-46 (Compound 36) is an efficient and highly selective HPK1 reverse indazole inhibitor with an IC₅₀ value of 1.1 nM. HPK1-IN-46 exhibits high selectivity for CDK2, JAK1, and JAK2. HPK1-IN-46 inhibits SLP76 phosphorylation mediated by HPK1, reverses T-cell inhibition, and enhances anti-tumor immunity. HPK1-IN-46 can be used in immunotherapy research for tumors.

HPK1-IN-53 (compund 3a) is the potent HPK1 inhibitor (IC₅₀=48 nM).

HPK1-IN-25 (example 94) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a enzymatic activity IC₅₀ of 129 nM. HPK1-IN-25 has the potential for cancer research.